Nutrition Considerations in Duchenne Muscular Dystrophy

Nutrition in Clinical Practice

Volumn 30, Issue 4, 2015, Pages 511-521

  Davis, Jillian ^a   Samuels, Emily ^a   Mullins, Lucille ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Duchenne muscular dystrophy; muscular dystrophies; nutrition assessment; nutrition therapy; nutritional support

Indexed keywords

DEFLAZACORT; PREDNISONE; CORTICOSTEROID; PROTEIN INTAKE;

ALTERNATIVE MEDICINE; ANTHROPOMETRY; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONSTIPATION; CORTICOSTEROID THERAPY; DIET THERAPY; DUCHENNE MUSCULAR DYSTROPHY; FEEDING DIFFICULTY; GASTROINTESTINAL REFLUX; GASTROSTOMY; HUMAN; NUTRITION; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; RESTING ENERGY EXPENDITURE; REVIEW; STOMACH EMPTYING; WEIGHT GAIN; ADOLESCENT; ADULT; CHILD; COMPLICATION; DIETARY FIBER; DIETARY SUPPLEMENT; DRINKING; ENERGY METABOLISM; ENTERIC FEEDING; MALE; MALNUTRITION; MUSCULAR DYSTROPHY, DUCHENNE; OVERNUTRITION; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; PROTEIN INTAKE; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BODY COMPOSITION; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; COMPLEMENTARY THERAPIES; CONSTIPATION; DIETARY FIBER; DIETARY PROTEINS; DIETARY SUPPLEMENTS; DRINKING; ENERGY METABOLISM; ENTERAL NUTRITION; GASTRIC EMPTYING; HUMANS; MALE; MALNUTRITION; MUSCULAR DYSTROPHY, DUCHENNE; OVERNUTRITION; YOUNG ADULT;

EID: 84937901049     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533615586202     Document Type: Review

References (90)

1. Emery AE,. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord. 1991; 1: 19-29.
2. Letellier G, Mok M, Alberti C,. Effect of glutamine on glucose metabolism in children with Duchenne muscular dystrophy. Clin Nutr. 2013; 32 (3): 386-390.
3. Liew WKM, Kang PB,. Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Ther Adv Neurol Disord. 2013; 6 (3): 147-160.
4. Pane M, Vasta I, Messina S,. Feeding problems and weight gain in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2006; 10 (5-6): 231-236.
5. Bushby K, Finkel R, Birnkrant DJ,. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9 (1): 77-93.
6. Bushby K, Bourke J, Bullock R, Eagle M, Gibson M, Quinby J,. The multidisciplinary management of Duchenne muscular dystrophy. Curr Pediatr. 2005; 15: 292-300.
7. Moxley RT, Pandya S, Ciafaloni E, Fox D, Campbell K,. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 25 (9): 1116-1129.
8. Willig TN, Carlier L, Legrand M, Riviere H, Navarro J,. Nutritional assessment in Duchenne muscular dystrophy. Dev Med Child Neurol. 1993; 35 (12): 1074-1082.
9. Aloysius A, Born P, Kinal M, Davis T, Pane M, Mercuri E,. Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies. Eur J Pediatr Neurol. 2008; 12 (3): 239-245.
10. Martigne L, Seguy D, Pellegrini,. Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr. 2010; 29 (1): 60-64.
11. Bushby K, Finkel R, Birnkrant DJ,. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010; 9 (3): 177-189.
12. Borrelli O, Salvia G, Mancini V,. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroenterol. 2005; 100 (3): 695-702.
13. Weber TK, Toporovski MS, Tahan S, Neufeld CB, de Morais MB,. Dietary fiber mixture in pediatric patients with controlled chronic constipation. J Pediatr Gastroenterol Nutr. 2014; 58 (3): 297-302.
14. Nabukera S, Romitti P, Campbell K,. Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy. J Child Neurol. 2012; 27 (6): 734-740.
15. Griffiths RD, Edwards RH,. A new chart for weight control in Duchenne muscular dystrophy. Arch Dis Child. 1988; 63: 1256-1258.
16. Sarrazin E, Hagen MV, Schara U, Au KV, Kaindl AM,. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2014; 18 (1): 38-44.
17. Nagal BH, Mortier W, Elmlinger M, Wollmann HA, Schmitt K, Ranke MB,. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr. 1999; 88 (1): 62-65.
18. West NA, Yang ML, Weitzenkamp DA,. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr. 2013; 163 (6): 1759-1763.
19. Centers for Disease Control and Prevention. Growth charts. http://www.cdc.gov/growthcharts/. Updated 9, 2010. Accessed January 5, 2015.
20. McDonald CM, Abresch RT, Carter GT,. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehab. 1995; 74 (5): S70-S92.
21. Zatz M, Opitz JM,. Effects of genetic counseling on Duchenne muscular dystrophy families in Brazil. Am J Med Genet. 2005; 15 (3): 483-490.
22. Ekvall S, Ekvall VK,. Pediatric Nutrition in Chronic Diseases and Developmental Disorders. New York, NY: Oxford University Press; 2005: 50.
23. ten Dam K, de Groot IJM, Noordam C,. Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen. Neuromuscul Disord. 2012; 22 (6): 500-504.
24. Kinali M, Main M, Eliahoo J,. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2007; 11: 160-166.
25. Sussman MD,. Advantage of early spinal stabilization and fusion in patients with Duchenne muscular dystrophy. J Pediatr Orthop. 1984; 4 (5): 532-537.
26. Hsu JD, Quinlivan R,. Scoliosis in Duchenne muscular dystrophy (DMD). Neuromuscul Disord. 2013; 23: 611-617.
27. Oda T, Shimizu N, Yonenobu K, Ono K, Nabeshima T, Kyoh S,. Longitudinal study of spinal deformity in Duchenne muscular dystrophy. J Pediatr Orthop. 1993; 13 (4): 478-488.
28. Cervellati S, Bettini N, Moscato M, Gusella A, Dema E, Maresi R,. Surgical treatment of spinal deformities in Duchenne muscular dystrophy: a long term follow-up study. Eur Spine J. 2004; 13 (5): 441-448.
29. Kurz LT, Mubarak SJ, Schultz P, Park SM, Leach J,. Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. J Pediatr Orthop. 1983; 3 (3): 347-353.
30. Skalsky AJ, Han JJ, Abresch RT, Shin CS, McDonald CM,. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle Nerve. 2009; 39 (5): 647-651.
31. Pessolano FA, Suarez AA, Mesa L, Dubrovsky A, Roncoroni AJ, De Vito EL,. Nutritional assessment of patients with neuromuscular diseases. Am J Phys Med Rehabil. 2003; 82 (3): 182-185.
32. Mok E, Letellier G, Cuisset JM, Denjean A, Gottrand F, Hankard R,. Assessing change in body composition in children with Duchenne muscular dystrophy: anthropometry and bioelectrical impedance analysis versus dual-energy X-ray absorptiometry. Clin Nutr. 2010; 29 (5): 633-638.
33. Palmieri GM, Bertorini TE, Griffin JW, Igarashi M, Karas JG,. Assessment of whole body composition with dual energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve. 1996; 19 (6): 777-779.
34. Elliott SA, Davidson ZE, Davies PS, Truby H,. A bedside measure of body composition in Duchenne muscular dystrophy. Pediatr Neurol. 2015; 52 (1): 82-87.
35. Zanardi MC, Tagliabue A, Orcesi S, Berardinelli A, Uggetti C, Pichiecchio A,. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutr. 2003; 57 (2): 273-278.
36. Tarnopolsky MA, Mahoney DJ, Vajsar J,. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004; 62 (10): 1771-1777.
37. Elliot SA, Davidson ZE, Davies PS, Truby H,. Predicting resting energy expenditure in boys with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2012; 16: 631-635.
38. Gonzalez-Bermejo J, Lofaso F, Falaize L,. Resting energy expenditure in Duchenne patients using home mechanical ventilation. Eur Respir J. 2005; 25: 682-687.
39. Haugen HA, Chan L, Li F,. Indirect calorimetry: a practical guide for clinicians. Nutr Clin Pract. 2007; 22 (4): 377-388.
40. Gallagher D, Belmonte D, Duerenberg P,. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol. 1998; 275 (2, pt 1): 249-258.
41. Henes ST, Cummings DM, Hickner RC,. Comparison of predictive equations and measured resting energy expenditure among obese youth attending a pediatric healthy weight clinic: one size does not fit all. Nutr Clin Pract. 2013; 28 (5): 617-624.
42. Davidson ZE, Truby H,. A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet. 2009; 22 (5): 383-393.
43. Shimizu-Fujiwara M, Komaki H, Nakagawa E,. Decreased resting energy expenditure in patients with Duchenne muscular dystrophy. Brain Dev. 2012; 34 (3): 206-212.
44. Hogan SE,. Body composition and resting energy expenditure of individuals with Duchenne and Becker muscular dystrophy. Can J Diet Pract Res. 2008; 69: 208-212.
45. Hankard RG, Gotrand F, Turck D, Carpentier A, Romon M, Farriaux JP,. Resting energy expenditure and energy substrate utilization in children with Duchenne muscular dystrophy. Pediatr Res. 1996; 40: 29-33.
46. Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B,. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord. 2011; 21 (4): 298-303.
47. Academy of Nutrition and Dietetics: Behavioral Health Nutrition Dietetic Practice Group and Pediatric Nutrition Practice Group. Pocket Guide to Children with Special Health Care and Nutritional Needs. Chicago, IL: Academy of Nutrition and Dietetics; 2012: 38-41.
48. Bunting KD, Mills J, Ramsey E, Rich S, Trout S,. Texas Childrens Hospital Pediatric Nutrition Reference Guide. 10th ed. Houston, TX: Texas Childrens Hospital; 2013: 26-27.
49. McGrail A, Kelchner L,. Barriers to oral fluid intake: beyond thickened liquids. J Neurosci Nurs. 2015; 47 (1): 58-63.
50. Holliday MA, Seger WE,. The maintenance need for water in parenteral fluid therapy. Pediatrics. 1957; 19 (5): 823-832.
51. Willig TN, Paulus PT, Lacau Saint Guily J, Beon C, Navarro J,. Swallowing problems in neuromuscular disorders. Arch Phys Med Rehabil. 1994; 75: 1175-1181.
52. National Dysphagia Diet Task Force. National Dysphagia Diet. Chicago, IL: American Dietetic Association; 2002.
53. Boland BJ, Silbert PL, Groover RV, Wollan PC, Silverstein MD,. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol. 1996; 14 (1): 7-12.
54. Gottrand F, Guillonneau I, Carpentier A,. Segmental colonic transit time in Duchenne muscular dystrophy. Arch Dis Child. 1991; 66 (10): 1262.
55. Winge K, Rasmussen D, Werdelin LM,. Constipation in neurological diseases. J Neurol Neurosurg Psychiatry. 2003; 74 (1): 13-19.
56. Nelms M, Sucher KP, Lacey K, Roth SL,. Nutrition Therapy & Pathophysiology. 2nd ed. Belmont, CA: Brooks/Cole Cengage Learning; 2010.
57. Lo Cascio CM, Latshang TD, Kohler M, Fehr T, Bloch K,. Severe metabolic acidosis in adult patients with Duchenne muscular dystrophy. Respiration. 2014; 87 (6): 499-503.
58. King WM, Ruttencutter R, Nagaraja HN,. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007; 68: 1607-1613.
59. Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, MD STARnet. Corticosteroid treatments in males with Duchenne muscular dystrophy: treatment duration and time to loss of ambulation. [published online 20, 2014 ]. J Child Neurol.
60. Ricotti V, Ridout DA, Scott E,. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013; 84 (6): 698-705.
61. Angelini C, Peterle E,. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 2012; 31 (1): 9-15.
62. Mayo AL, Craven BC, McAdam LC, Biggar WD,. Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord. 2013; 22 (12): 1040-1045.
63. Boot AM, Engels MA, Boerma GJ, Krenning EP, de Muinck Keizer-Schrama SM,. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab. 1997; 82 (8): 2423-2428.
64. Fewtrell MS,. Bone densitometry in children assessed by dual X-ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003;(88): 795-798.
65. National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: calcium-health professional fact sheet. http://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/. Updated 21, 2013. Accessed January 5, 2014.
66. Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL,. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord. 2005; 15 (1): 80-85.
67. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2010.
68. U.S. Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for Standard Reference., Release 27. http://www.ars.usda.gov/ba/bhnrc/ndl. Updated 2, 2014. Accessed January 6, 2014.
69. Straub DA,. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007; 22 (3) 286-296.
70. Tsao CY,. Muscle disease. Pediatr Rev. 2014; 35 (2): 49-61.
71. Dietz WH,. Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics. 1998; 101 (3): 518-525.
72. Krebs NF, Himes JH, Jacobson D,. Assessment of child and adolescent overweight and obesity. Pediatrics. 2007; 120: 193-228.
73. Kleinman RE,. Pediatric Nutrition Handbook. Elk Grove Village, IL: American Academy of Pediatrics; 2009: 759-782.
74. Freeland-Graves JH, Nitzke S,. Position of the Academy of Nutrition and Dietetics: total diet approach to healthy eating. J Acad Nutr Diet. 2013; 113 (2): 302-317.
75. Ogata BN, Hayes D,. Position of the Academy of Nutrition and Dietetics: nutrition guidance for healthy children ages 2 to 11 years. J Acad Nutr Diet. 2014; 114 (8): 1257-1276.
76. Radley HG, De Luca A, Lynch GS, Grounds MD,. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell B. 2007; 39 (3): 469-477.
77. Buetler TM, Renard M, Offord EA, Schneider H, Ruegg UT,. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr. 2002; 75 (4): 749-753.
78. Gordon BS, Diaz DCD, Kostek MC,. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin Nutr. 2013; 32: 104-111.
79. De Luca A, Pierno S, Liantonio A,. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther. 2003; 304 (1): 453-463.
80. Passaquin AC, Renard M, Kay L,. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002; 12 (2): 174-182.
81. Brinkmeyer-Langford C, Kornegay JN,. Comparative genomics of X-linked muscular dystrophies: the Golden Retriever model. Curr Genomics. 2013: 14 (5): 330-342.
82. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ,. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989; 244 (4912): 1578-1580.
83. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA,. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007; 21 (9): 2195-2204.
84. Pastoret C, Sebille A,. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci. 1995; 129 (2): 97-105.
85. Dorchies OM, Wagner S, Vuadens O,. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006; 290 (2): C616-C625.
86. Spurney CF, Rocha CT, Henricson E,. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve. 2011; 44 (2): 174-178.
87. Holecek M,. Side effects of long-term glutamine supplementation. JPEN Parenter Enteral Nutr. 2012; 37 (5): 607-616.
88. Hankard RG, Hammond D, Haymond M, Darmaun D,. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998; 43: 222-226.
89. Qureshi MM, McClure WC, Arevalo NL,. The dietary supplement protandim decreases plasma osteopontin and improves markers of oxidative stress in muscular dystrophy mdx mice. J Diet Suppl. 2010; 7 (2): 159-178.
90. Mok E, Violante CE, Daubrosse C,. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr. 2006; 83 (4): 823-828.